MedPath

Methylergometrine

Generic Name
Methylergometrine
Brand Names
Methergine
Drug Type
Small Molecule
Chemical Formula
C20H25N3O2
CAS Number
113-42-8
Unique Ingredient Identifier
W53L6FE61V
Background

A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)

Indication

For the prevention and control of excessive bleeding following vaginal childbirth

Associated Conditions
Angina Pectoris, Variant, Postpartum Haemorrhage (PPH), Postpartum uterine subinvolution, Uterine Atony, Uterine Hemorrhage
Clinical Trials
Related News

Prophylactic Methylergonovine for Twin Cesarean

Phase 4
Completed
Conditions
Twin; Complicating Pregnancy
Postpartum Hemorrhage
Interventions
Drug: Placebo
First Posted Date
2023-03-16
Last Posted Date
2024-11-05
Lead Sponsor
Columbia University
Target Recruit Count
66
Registration Number
NCT05772156
Locations
🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients

Phase 4
Completed
Conditions
Uterine Atony With Hemorrhage
Interventions
Drug: Normal Saline (placebo)
First Posted Date
2019-04-05
Last Posted Date
2022-08-01
Lead Sponsor
Cynthia Wong
Target Recruit Count
160
Registration Number
NCT03904446
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial

Phase 4
Active, not recruiting
Conditions
Postpartum Hemorrhage
Uterine Atony
Interventions
Drug: 15-methyl prostaglandin F2α
First Posted Date
2018-07-12
Last Posted Date
2022-05-25
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
100
Registration Number
NCT03584854
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections

Early Phase 1
Withdrawn
Conditions
Uterine Atony
Postpartum Hemorrhage
Uterine Tone Disorders
Interventions
First Posted Date
2017-10-05
Last Posted Date
2020-08-03
Lead Sponsor
Johns Hopkins University
Registration Number
NCT03303235
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

Uterotonic Prophylaxis Trial

Phase 4
Completed
Conditions
Hemorrhage
Interventions
Other: placebo
First Posted Date
2015-04-06
Last Posted Date
2019-09-06
Lead Sponsor
University of California, San Francisco
Target Recruit Count
284
Registration Number
NCT02408965
Locations
🇺🇸

SFGH Women's Options Center, San Francisco, California, United States

Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine

Not Applicable
Completed
Conditions
Endometritis
Interventions
First Posted Date
2009-03-10
Last Posted Date
2012-09-19
Lead Sponsor
University of South Florida
Target Recruit Count
44
Registration Number
NCT00858832
Locations
🇺🇸

Tampa General Hospital, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy